Welcome to the new Gustave Roussy website
A new website designed to offer you a simpler, clearer, and more intuitive experience. Patients, caregivers, healthcare professionals, and donors: find information, news, and services more easily.
Gustave Roussy at the ESMO 2018 Congress
This year, the European Society for Medical Oncology (ESMO) will take place in Munich, Germany, from 19 to 23 October. It is Europe’s biggest cancer congress and the number of delegates increases year-on-year. Experts from all over the world visit the congress to share the latest clinical innovations in oncology. Around 20,000 delegates from 130 countries are expected to attend ESMO 2018.
Published on
Changed on
This year, the European Society for Medical Oncology (ESMO) will take place in Munich, Germany, from 19 to 23 October. It is Europe’s biggest cancer congress and the number of delegates increases year-on-year. Experts from all over the world visit the congress to share the latest clinical innovations in oncology. Around 20,000 delegates from 130 countries are expected to attend ESMO 2018.
Gustave Roussy will undoubtedly be one of the main stakeholders at this congress and specialists will present results during oral presentations, poster discussions and special symposia/posters.
Professor Fabrice André’s oral presentation of the results of the SOLAR-1 breast cancer study during the plenary session on Saturday, 20 October, is one of the highlights of the congress.
Renowned for their specialist knowledge, approximately ten experts will act as moderators in the oral sessions, symposia or discussions. Professor Karim Fizazi will officiate during a plenary session oral presentation on prostate cancer on Sunday 21 October.
Professor Alexander Eggermont, Gustave Roussy Director General, will be the speaker at a "special symposium" session focussing on therapeutic strategies for melanoma and outlining future plans for adjuvant immunotherapy treatments.
Gustave Roussy main presentations at ESMO 2018
- Advanced hormone-dependent breast cancer: Is the first medication to target a genome anomaly in the pipeline?
Plenary Session | Pr Fabrice André | Read the Press Release
- Breast cancer: treatment compliance for women receiving tamoxifen?
Oral | Dr Barbara Pistilli | Read ESMO Press Release
Change of practices
- High-risk, localised prostate cancer: is it better to use a chemotherapy right from the outset?
Oral | Pr Karim Fizazi
- Squamous cell carcinoma: Evidence of intensity-modulated radiotherapy
Discussion | Dr Yungan Tao -
Efficacy of lenvatinib in Radioiodine-refractory Differentiated Thyroid Cancer
Discussion | Dr Sophie Leboulleux
New and promising avenue in phase I trial
- Neuroendocrine tumours: Good perspective with an epigenetic target
Discussion | Dr Antoine Hollebecque
Immunotherapy
- Metastatic renal cancer: a review of the use of Nivolumab in the management of cerebral metastases
Discussion | Dr Ronan Flippot
- Treatment by immunotherapy: what is the link between efficacy and adverse events?
Discussion | Dr Maria Kfoury
Expert in the management of sarcoma
- Rare peritoneal malignant disease: a cure is possible for patients with a dermoplastic small round cell tumour
Discussion | Dr Charles Honoré
- Metastatic sarcomas: quality of life maintained with trabectedine
Discussion | Dr Axel Le Cesne
Improve treatment toxicity and adverse events
- Physical activity and weight: Important parameters in combating chemo-induced neuropathies
Discussion | Dr Margarida Matias - Severe fatigue after breast cancer: Identify the patients at risk
Discussion | Dr Ines Vaz Luis - Adjuvant chemotherapy in breast cancer : Impact of physical activity on quality of life
Discussion | Dr Antonio Di Meglio
▶ More information in our press kit
All Gustave Roussy's news at ESMO 2018 on Twitter: @GustaveRoussy
Last news
-
Breast Cancer: Gustave Roussy Ranked No. 1 in France for Breast Surgery and Breast Reconstruction
On the occasion of Breast Cancer Awareness Month, the 2025 data from Visuchir, the national surgical activity monitoring tool of the French Health Insurance system, places Gustave Roussy in first position for both breast surgery and breast reconstruction. Beyond this ranking, these figures highlight that reconstruction is now an integral part of breast cancer treatment. It is considered at every stage of care: from tumor removal surgery, whether lumpectomy or mastectomy, through to the post-cancer period, helping to restore the body and support women in regaining their physical integrity and quality of life.
-
Newsweek Ranking: Gustave Roussy Named Europe’s Leading Cancer Centre and Third Best Worldwide
The 2027 edition of Newsweek’s World's Best Specialized Hospitals ranking once again recognises Gustave Roussy as the leading cancer centre in France and Europe, and the third best worldwide. This distinction highlights the excellence of the Institute’s care and research, as well as the daily commitment of all its professionals.
-
Living with and beyond cancer: the promises and challenges of digital health
In a Viewpoint article published in The Lancet Digital Health, Drs Ines Vaz-Luis and Maria Alice Franzoi, together with Emmanuel Mussault, a patient partner at the PRISM University Hospital Institute, examine the role that digital tools can play in supporting people living with and beyond cancer. Their central message is that these technologies can support more personalised and accessible care, but their value depends primarily on how they are integrated into care pathways, the human support provided, their ability to address individual needs and their evaluation in real-world settings.
-
Gustave Roussy and The Lancet launch an international lecture series on innovations transforming cancer care
The inaugural lecture in the “Lecture Series on Cancer Breakthroughs” will take place on Friday 18 September at 5:00 pm. It will be delivered by Professor Timothy R. Rebbeck, a leading cancer prevention specialist at Harvard University and the Dana-Farber Cancer Institute.
